TI
LYEL icon

Trexquant Investment’s Lyell Immunopharma LYEL Stock Holding History

Trexquant Investment’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,275
Closed -$167K – 1788
2025
Q3 		$167K Buy
+10,275
New +$117K ﹤0.01% 1513

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
MCL
MWG Caph Ltd Charlestown $72.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Trexquant Investment's LYEL Position: Q4 2025 in Review

Trexquant Investment sold out of Lyell Immunopharma (LYEL) in Q4 2025, closing a stake of 10,275 shares — an estimated $167K sold.

Trexquant Investment first reported a position in LYEL in Q3 2025 and held it in 1 quarter. The position peaked at $167K in Q3 2025. 68 funds tracked by Wall St. Rank hold LYEL as of Q4 2025.

  • Trexquant Investment reported no remaining Lyell Immunopharma position as of Q4 2025 after selling out during the quarter.
  • Trexquant Investment sold 10,275 Lyell Immunopharma shares in Q4 2025, an estimated $167K.
  • Trexquant Investment first reported a position in Lyell Immunopharma in Q3 2025 and held it in 1 quarter.
  • Trexquant Investment's Lyell Immunopharma position peaked at $167K in Q3 2025.
  • 68 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2025.

Based on Trexquant Investment's 13F filing for Q4 2025, filed 17 Feb 2026.